

# Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1

Sharon L. Hillier,<sup>1,2</sup> Linda-Gail Bekker,<sup>3,4</sup> Sharon A. Riddler,<sup>2,5</sup> Craig W. Hendrix,<sup>4,6</sup> Sharlaa Badal-Faesen,<sup>5</sup> Pippa Macdonald,<sup>3,7</sup> Gonasagrie Nair,<sup>3</sup> Johannes Lombaard,<sup>6</sup> Yoseph Caraco,<sup>7,8</sup> Avivit Peer,<sup>8</sup> Munjal Patel,<sup>9,10</sup> Ryan Vargo,<sup>9,11</sup> Brenda Homony,<sup>9</sup> Katherine Nedrow,<sup>9</sup> Barbara Evans,<sup>9</sup> Prachi Wickremasingha,<sup>9</sup> Yun-Ping Zhou,<sup>9</sup> Valerie Teal,<sup>9,a</sup> Peggy Hwang,<sup>9,12</sup> Ciaran McMullan,<sup>9</sup> Keith D. Kaufman,<sup>9,a</sup> Michael N. Robertson,<sup>9,a,13</sup> and Rebeca M. Plank<sup>9,14</sup>

<sup>1</sup>Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute and Foundation, Pittsburgh, Pennsylvania, USA; <sup>2</sup>Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; <sup>3</sup>Department of Medicine, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; <sup>4</sup>Department of Medicine (Clinical Pharmacology), The John Hopkins Hospital, Baltimore, Maryland, USA; <sup>5</sup>Clinical HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; <sup>6</sup>Research and Development, Josha Research, Bloemfontein, South Africa; <sup>7</sup>Clinical Pharmacology Unit, Division of Medicine, Hadassah Medical Center, Jerusalem, Israel; <sup>8</sup>Department of Oncology, Rambam Health Care Campus, Haifa, Israel; and <sup>9</sup>MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA

**Background.** Islatravir, a nucleoside reverse transcriptase translocation inhibitor, exhibits high potency against human immunodeficiency virus type 1 (HIV-1), with a long intracellular half-life. The safety, tolerability, and pharmacokinetics of once-monthly oral islatravir were evaluated in adults at low risk of acquiring HIV-1.

**Methods.** In this double-blind, placebo-controlled trial, participants were randomized 2:2:1 to receive 6 once-monthly doses of islatravir 60 mg, islatravir 120 mg, or placebo. Objectives included assessing safety, tolerability, and pharmacokinetic profiles of islatravir in plasma and its active metabolite, islatravir triphosphate (ISL-TP), in peripheral blood mononuclear cells (PBMCs).

**Results.** Of 242 participants (islatravir 60 mg, n = 97; islatravir 120 mg, n = 97; placebo, n = 48), most were aged ≤45 years (90.1%), female (67.4%), and White (52.9%). Proportions of participants experiencing ≥1 adverse event (AE) were similar in the islatravir (60 mg: 68.0%; 120 mg: 64.9%) and placebo (75.0%) arms. AEs were generally mild to moderate, with infection-related AEs comparable across arms. Lymphocyte count decreased in the islatravir arms, with mean percentage changes of  $-21.3\% \pm 20.1\%$  (60 mg) and  $-35.6\% \pm 22.8\%$  (120 mg) versus  $+4.4\% \pm 25.9\%$  (placebo) at week 24. Median intracellular PBMC ISL-TP concentrations remained above the prespecified pharmacokinetic threshold for HIV-1 prophylaxis (0.050 pmol/10<sup>6</sup> cells) through 4 weeks after the first dose and ≥8 weeks after the last dose.

**Conclusions.** Oral islatravir 60 mg and 120 mg once monthly demonstrated similar tolerability and AE profiles to placebo, except for dose-dependent decreases in total lymphocyte counts. A partial recovery in total lymphocyte counts was observed. In most participants, both islatravir doses achieved PBMC ISL-TP exposure levels projected to be effective for once-monthly oral HIV-1 preexposure prophylaxis.

**Clinical Trials Registration.** NCT04003103.

**Keywords.** preexposure prophylaxis; PrEP; nucleoside reverse transcriptase translocation inhibition; long-acting; islatravir.

Received 13 November 2024; editorial decision 22 April 2025; published online 6 May 2025  
Presented in part: HIV Research for Prevention, Virtual, 27–28 January and 3–4 February 2021; 11th International AIDS Society Conference on HIV Science, Berlin, Germany and Virtual, 18–21 July 2021; Conference on Retroviruses and Opportunistic Infections, Virtual, 12–16 February 2022; and XII National GeSIDA Congress, Málaga, Spain, 29 November–2 December 2021.

<sup>a</sup>V. T., K. D. K., and M. N. R. were employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA, at the time the study was conducted.

Correspondence: Rebeca M. Plank, MD, MPH, MRL Research Laboratories, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA (rebeca.plank@merck.com).

The Journal of Infectious Diseases® 2025;232:1050–60

© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.  
<https://doi.org/10.1093/infdis/jiaf222>

Innovations in human immunodeficiency virus type 1 (HIV-1) preexposure prophylaxis (PrEP) options are needed to meet the diverse needs of individuals who could benefit from PrEP. Despite efforts to expand HIV treatment and the global recommendation for provision of oral PrEP [1, 2], approximately 1.5 million new HIV infections occurred worldwide in 2022, equating to approximately 4000 people acquiring HIV daily [3].

Current PrEP modalities include daily oral, monthly vaginal ring, and long-acting injectable options [4]. Adherence remains a challenge for daily oral PrEP [5, 6], the vaginal ring is discreet but not widely accessible outside Africa [7–13], and long-acting

injectable PrEP requires administration by healthcare providers [14, 15]. Additional options for HIV-1 prevention, including discreet, self-administered, long-acting agents, are needed to overcome barriers associated with low PrEP uptake, adherence, and persistence [16–21].

Nucleoside reverse transcriptase translocation inhibitors (NRTTIs) show promise for treatment and prevention of HIV-1 [22, 23]. Islatravir (ISL), an NRTTI currently being investigated for treatment of HIV-1 [24–26], has high potency, a long half-life ( $t_{1/2}$ ), a favorable drug resistance profile, and broad pharmacologic distribution [27]. The potency of ISL, coupled with the long intracellular  $t_{1/2}$  of its active form, islatravir triphosphate (ISL-TP), support its potential as a once-monthly (QM) oral dosing regimen for HIV-1 PrEP.

Based on efficacious concentrations observed in preclinical and early clinical studies [24, 28], a pharmacokinetic (PK) threshold of 0.050 pmol/ $10^6$  cells for ISL-TP in peripheral blood mononuclear cells (PBMCs) was established for HIV-1 prevention [29, 30]. ISL 60 mg is anticipated to achieve this threshold for  $\geq 4$  weeks after dosing, based on PK modeling analyses.

This study evaluated the safety, tolerability, and PK of oral ISL (60 mg and 120 mg) given QM for 6 doses, compared with placebo, in adults at low risk of acquiring HIV-1.

## METHODS

### Study Design and Participants

This randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase 2a study (MK-8591-016; NCT04003103) evaluated oral ISL QM in adults without HIV and at low risk of acquiring HIV-1. An optional unblinded follow-up phase collected additional PK samples (PBMC/PK bridging subset; Figure 1). The study adhered to Good Clinical Practice principles and received approval from appropriate institutional


review boards and regulatory agencies. Written informed consent was obtained before participant screening. Conducted during the coronavirus disease 2019 (COVID-19) pandemic, the study followed health authority guidance from the US Food and Drug Administration and the European Medicines Agency. Measures were implemented to ensure participant and staff safety, maintain Good Clinical Practice compliance, and preserve data integrity. Contingency measures tailored to each country, region, and study site were executed per standard operating procedures for exception and deviation management. All exceptions and deviations were documented.

Participants were enrolled at 9 investigational centers in Israel, South Africa, and the United States. Eligible participants were aged 18–65 years and generally in good health (Supplementary Table 1).

### Study Intervention and Procedures

The study included a screening period ( $\leq 45$  days), intervention period (24 weeks), 12-week postintervention follow-up period, and an optional 32-week unblinded extended follow-up phase for the collection of ISL PBMC PK samples (the PBMC/PK bridging subset; Figure 1). Sponsor personnel were unblinded at week 24 for interim safety evaluation, while participants and investigators/clinical site personnel remained blinded through week 36 (ie, the 12-week postintervention follow-up period). After week 36, participants and investigators/clinical site personnel were unblinded to study intervention but remained blinded to ISL dose.

Participants were randomized (2:2:1, stratified by sex assigned at birth and region [Africa, non-Africa]) to receive 6 doses of ISL 60 mg, ISL 120 mg, or placebo every 4 weeks for 20 weeks. Participants received an observed oral dose of the assigned blinded study intervention every 4 weeks, starting on day 1, followed by weeks 4, 8, 12, 16, and 20, with the final



**Figure 1.** Study schema and treatment plan. <sup>a</sup>Randomization to study intervention at day 1 and stratified by sex assigned at birth (female, male) and region (Africa, non-Africa). <sup>b</sup>Sponsor was unblinded at week 24 to allow for an interim evaluation of safety. Participants and investigators/clinical site personnel remained blinded up to week 36. <sup>c</sup>After week 36, only participants in the peripheral blood mononuclear cell/pharmacokinetic (PK) bridging substudy who were initially randomized to islatravir had an additional 32-week extended, unblinded PK follow-up through week 68. Abbreviations: DDI, drug–drug interaction; HIV, human immunodeficiency virus; ISL, islatravir; ISL-TP, islatravir triphosphate; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics; QM, once monthly.

dosing period through the week 24 visit (including a 14-day window). Participants were followed every 4 weeks for a follow-up period of 12 weeks after the last dosing period (ie, for 12 weeks beyond week 24) through week 36. Participants who discontinued study intervention before week 20 were encouraged to complete all of the follow-up visits.

Adverse events (AEs) were collected at each study visit and were graded according to the Division of AIDS (DAIDS; version 2.1) criteria [31]. Laboratory safety tests included chemistry, hematology, urine point-of-care dipstick, urinalysis, and HIV screening.

Per the original study protocol (19 June 2019), lymphocyte subsets (including CD4<sup>+</sup> and CD8<sup>+</sup> T-cell counts) were not collected. In response to findings of decreases in lymphocytes and CD4<sup>+</sup> T cells in other ISL studies [32], the protocol was amended (8 December 2021) to include additional blood samples for measurement of total lymphocyte, CD4<sup>+</sup>, and CD8<sup>+</sup> T-cell counts. After study unblinding, lymphocyte data were collected through week 68 (48 weeks after the last dose of drug) in the subset of participants who remained in the trial when these additional laboratory collections were added to the protocol (n = 34). Only serious AEs and nonserious AEs related to study procedures were collected during this extended follow-up.

Median percentage change in weight and metabolic parameters (peripheral fat, trunk fat, and bone mineral density [BMD]) were measured by dual X-ray absorptiometry scans at day 1 and week 24.

Blood samples for determination of levels of ISL in plasma and ISL-TP in PBMC analysis were collected from participants from day 1 through week 24. Predose PK and PBMC samples were collected at visits at day 1 and weeks 4, 8, 12, 16, and 20, with an additional sample taken 30 minutes postdose at day 1, 24 hours after day 1 dose, and week 20. Participants in the PBMC/PK bridging subset who had been randomized to ISL continued into a 32-week unblinded PK follow-up through week 68, with PBMC samples collected at 4 additional visits.

## Outcomes

### Safety Outcomes

The primary safety outcomes were the incidence of AEs through week 36 and discontinuations due to AEs through week 20. A secondary objective was to evaluate the safety and tolerability of 6 QM doses of ISL (60 mg and 120 mg) through 4 weeks after the last dose (week 24) based on the overall AE profile, including drug-related AEs and serious AEs, and changes in laboratory values.

### Pharmacokinetic Outcomes

Characterizing the plasma PK profile of ISL was another secondary objective, and characterizing the intracellular PK profile of ISL-TP in PBMCs up to 48 weeks after the last dose of ISL (60 mg and 120 mg) was an exploratory objective of the PBMC/PK substudy. Plasma ISL concentrations and PBMC

ISL-TP concentrations were determined by Syneos Health (Quebec, Canada) using a validated high-performance and ultra-performance liquid chromatography–tandem mass spectrometry method, respectively [33, 34]. The analytical range for ISL plasma was  $6.82 \times 10^{-5}$  to  $6.82 \times 10^{-1}$   $\mu\text{mol/L}$  (0.0682–682.0 nmol/L), with the lower limit of quantitation (LLOQ) at  $6.82 \times 10^{-5}$   $\mu\text{mol/L}$  (0.0682 nmol/L). The analytical range for ISL-TP in PBMCs was  $1.88 \times 10^{-4}$  to  $7.50 \times 10^{-2}$   $\mu\text{mol/L}$  (0.188–75.0 nmol/L), with the LLOQ at  $1.88 \times 10^{-4}$   $\mu\text{mol/L}$  (0.188 nmol/L). PBMC cell counts (per  $10^6$  cells) were estimated using a hemocytometer, and the conversion from nmol/L to pmol/ $10^6$  cells used the standard assumption that 1 PBMC has an approximate volume of 0.2 pL [35, 36].

## Statistical Analysis


### Safety Analysis

All participants receiving  $\geq 1$  dose of study intervention were included in the safety population. Point estimates and 95% confidence intervals, for the difference between treatment groups in the proportion of participants with AEs and those who met predefined laboratory changes, were calculated by the Miettinen and Nurminen method. Additional planned safety assessments included mean change in renal parameters (serum creatinine and estimated glomerular filtration rate [eGFR] calculated by the Modification of Diet in Renal Disease equation).

### Pharmacokinetic Analysis

The plasma PK analysis population included participants treated with ISL who had available data from  $\geq 1$  dose of study intervention. Plasma ISL and PBMC ISL-TP concentrations and actual elapsed blood-sampling times relative to ISL time of dose were used to determine the PK profile of plasma ISL and PBMC ISL-TP following doses administered on day 1 and week 20. Plasma ISL and PBMC ISL-TP values below the LLOQ (BLOQ) were treated as 0, except for obvious outliers (eg, BLOQ appeared in the middle of an otherwise nonzero concentration–time profile), which were treated as missing.

The following PK parameter values were determined from concentration–time data by employing a noncompartmental approach using Phoenix WinNonlin software (version 8.1): area under the plasma concentration–time curve from dosing to 672 hours postdose ( $\text{AUC}_{0-672\text{h}}$ ), maximum concentration ( $C_{\text{max}}$ ), time to maximum concentration ( $T_{\text{max}}$ ), time to last measurable concentration, trough concentration ( $C_{\text{trough}}$ ), and apparent terminal elimination  $t_{1/2}$ .  $T_{\text{max}}$  values were obtained directly from the plasma and PBMC concentration–time data. AUCs were calculated using the linear-up/log-down method. The apparent terminal elimination  $t_{1/2}$  was calculated as  $(\ln[2]/\lambda_z)$ , where  $\lambda_z$  is the apparent first-order terminal elimination rate constant, calculated from the slope of the linear regression of the terminal log-linear portion of the plasma concentration–time profile.



**Figure 2.** Participant disposition for study medication. <sup>a</sup>Participants who became pregnant during the study were followed through completion of the infant safety follow-up when the infant reached 1 year of age; these participants did not have a final study status.

## RESULTS

### Study Participants

In total, 446 participants were screened and 242 were randomized and received  $\geq 1$  dose of ISL or placebo. Overall, 91.7% (222/242) of participants completed study medication (Figure 2) and 90.0% (218/242) completed the trial. The plasma PK analysis included 194 participants who had  $\geq 1$  dose of ISL ( $n = 97$  each in the ISL 60 mg and 120 mg groups). The PBMC/PK subset included 40 participants who received ISL 60 mg and 41 participants who received ISL 120 mg.

Baseline characteristics were comparable across treatment groups; most participants were aged  $\leq 45$  years (90.1%), female (67.4%), and White (52.9%), and the largest proportion of participants were from the United States (45.9%) (Table 1).

### Safety

#### Adverse Event Profile

The proportions of participants with  $\geq 1$  AE were generally comparable across the treatment groups through week 36: 68.0% (66/97) in the ISL 60 mg group, 64.9% (63/97) in the ISL 120 mg group, and 75.0% (36/48) in the placebo group. AEs resulted in discontinuation of study intervention in 2 participants: 1 from ISL 60 mg discontinued due to rash and pruritus (both grade 2), and 1 from ISL 120 mg discontinued due

to foreign body sensation (grade 1, lump in the throat); all 3 events were considered drug-related.

Overall AE profiles were generally comparable across treatment groups through the end of the active treatment period (Table 2), and most AEs were classified as grade 1 or 2. Overall,  $<5\%$  of participants had grade 3–5 AEs, and no AE was considered drug-related. No clinically meaningful differences between treatment groups were observed for AEs reported by  $\geq 4$  participants: the most frequently reported AE was headache in each ISL group, and diarrhea and abdominal pain in the placebo group. Two serious AEs were reported by 1 participant in the ISL 60 mg group during the active treatment period (intentional self-injury and loss of consciousness); neither event was considered drug-related.

Drug-related AEs were also comparable across treatment groups (Table 3). The most frequent drug-related AEs were headache and pruritus in the ISL 60 mg group, proteinuria in the ISL 120 mg group, and diarrhea in the placebo group.

During the unblinded follow-up period at week 44, a 29-year-old female in the ISL 120 mg group reported a fetal loss at approximately 11 weeks of gestation. It was estimated that the participant had conceived approximately 10 weeks after receiving the last dose of study medication at week 20; the investigator considered the event unrelated to the study drug. One participant in the ISL 60 mg group died from a cerebrovascular

**Table 1. Demographics and Baseline Characteristics**

| Characteristics           | ISL 60 mg<br>(n = 97) | ISL 120 mg<br>(n = 97) | Placebo<br>(n = 48) | Total<br>(N = 242) |
|---------------------------|-----------------------|------------------------|---------------------|--------------------|
| Age, y                    |                       |                        |                     |                    |
| Median (range)            | 32.0 (20–58)          | 31.0 (18–58)           | 30.0 (19–45)        | 31.0 (18–58)       |
| 18–45 y                   | 84 (86.6)             | 86 (88.7)              | 48 (100.0)          | 218 (90.1)         |
| Sex assigned at birth     |                       |                        |                     |                    |
| Female                    | 66 (68.0)             | 64 (66.0)              | 33 (68.8)           | 163 (67.4)         |
| Male                      | 31 (32.0)             | 33 (34.0)              | 15 (31.3)           | 79 (32.6)          |
| Country                   |                       |                        |                     |                    |
| Israel                    | 15 (15.5)             | 17 (17.5)              | 13 (27.1)           | 45 (18.6)          |
| South Africa              | 34 (35.1)             | 36 (37.1)              | 16 (33.3)           | 86 (35.5)          |
| United States             | 48 (49.5)             | 44 (45.4)              | 19 (39.6)           | 111 (45.9)         |
| Race                      |                       |                        |                     |                    |
| White                     | 55 (56.7)             | 44 (45.4)              | 29 (60.4)           | 128 (52.9)         |
| Black or African American | 37 (38.1)             | 48 (49.5)              | 16 (33.3)           | 101 (41.7)         |
| Other <sup>a</sup>        | 5 (5.2)               | 5 (5.2)                | 3 (6.3)             | 13 (5.4)           |

Data are presented as No. (%) unless otherwise indicated. One participant assigned male sex at birth was incorrectly recorded at randomization as female sex assigned at birth.

Abbreviation: ISL, islatravir.

<sup>a</sup>Other race includes Asian, American Indian, Alaska Native, or multiracial.

accident at week 64 (44 weeks after receiving the last dose at week 20), which was not considered drug-related by the investigator.

### Laboratory Tests

There were no clinically meaningful findings in predefined laboratory changes; results were comparable across groups with most treatment-emergent laboratory abnormalities being grade 1 or 2 ([Supplementary Table 2](#)). No participant had laboratory values that met criteria for drug-induced liver injury (alanine aminotransferase or aspartate aminotransferase  $\geq 3 \times$  upper limit of normal range [ULN], as well as bilirubin  $\geq 2 \times$  ULN and alkaline phosphatase  $< 2 \times$  ULN). The incidence of treatment-emergent abnormalities in serum creatinine or eGFR was not significantly different between the ISL and placebo groups ([Supplementary Table 2](#)). Mean changes from baseline in serum creatinine and eGFR values were small and similar across treatment groups at week 24 ([Supplementary Table 3](#)).

At week 24, the median percentage changes from baseline in weight, peripheral fat, and trunk fat were small ( $< 1\%$ ) and comparable for the ISL 60 mg and placebo groups ([Supplementary Table 3](#)). Participants in the ISL 120 mg group had small increases (2%–3%) in weight, peripheral fat, and trunk fat. Median percentage changes from baseline in total hip BMD and lumbar spine BMD were small and comparable across all groups ([Supplementary Table 3](#)).

### Change in Total Lymphocyte Counts and Other Hematologic Parameters

At week 24, 95% (181/191) of participants in the combined ISL groups had normal total lymphocyte counts (DAIDS grade 0;

$> 650$  cells/ $\mu\text{L}$ ). Of the 10 participants who had lymphocyte decreases that met DAIDS grading criteria (3 in the ISL 60 mg group and 7 in the ISL 120 mg group), 5 had grade 1 (600 to  $< 650$  cells/ $\mu\text{L}$ ), 3 had grade 2 (500 to  $< 600$  cells/ $\mu\text{L}$ ), and 2 had grade 3 (350 to  $< 500$  cells/ $\mu\text{L}$ ) AEs ([Supplementary Table 2](#)). None of the participants in the placebo group had lymphocyte decreases that met DAIDS grading criteria. Decreases from baseline in total lymphocyte counts were observed through week 36 for both ISL groups ([Figure 3](#)). The largest mean declines were observed at week 24:  $-21.3\% \pm 20.1\%$  and  $-35.6\% \pm 22.8\%$  for the ISL 60 mg and 120 mg groups, respectively, compared with a  $4.4\% \pm 25.9\%$  increase in the placebo group. By week 36 (ie, 12 weeks after the last dose), the mean lymphocyte declines had improved to  $-11.8\%$  and  $-29.4\%$  for the ISL 60 mg and 120 mg groups, respectively, compared with a 2.0% increase in the placebo group ([Figure 3](#)).

Lymphocyte data were collected through week 68 (48 weeks after the last dose of study intervention) in the subset of participants who were still in the trial when these additional laboratory collections were added to the protocol. At week 68, mean percentage changes from baseline in lymphocyte count were  $-9.7\%$  (ISL 60 mg) and  $-21.5\%$  (ISL 120 mg) ([Supplementary Table 4](#)). At weeks 60 and 68, mean  $\text{CD4}^+$  and  $\text{CD8}^+$  T-cell counts in this subset of participants were  $> 600$  cells/ $\mu\text{L}$  and  $> 300$  cells/ $\mu\text{L}$ , respectively, for both ISL groups ([Supplementary Table 5](#)).

At week 24, no increases in the incidence of infections were observed for participants receiving ISL compared with placebo, or for participants with a decrease in total lymphocyte counts of  $\geq 30\%$  compared with  $< 30\%$  ([Supplementary Table 6](#)). No clinically meaningful changes from baseline in other hematologic parameters were observed through weeks 36 and 68.

### Pharmacokinetics

For both ISL doses, biphasic decline was observed in plasma ISL and PBMC ISL-TP levels following peak concentrations; biphasic decline was more pronounced for ISL in plasma compared with ISL-TP in PBMCs ([Supplementary Figure 1](#)). The actual times for dosing and PK collection were noticeably different from protocol-scheduled times, which may have contributed to higher values for the geometric mean percent coefficient of variation ([Supplementary Table 7](#)). For the ISL 60 mg and 120 mg groups, the geometric mean terminal elimination  $t_{1/2}$  of ISL in plasma was 175 and 177 hours, and the  $t_{1/2}$  ISL-TP in PBMCs was 483 and 474 hours, respectively ( $> 2.5$  weeks; [Supplementary Table 7](#)). Median ISL-TP concentrations remained above the prespecified threshold for prophylaxis of 0.050 pmol/ $10^6$  cells through  $\geq 8$  weeks after the last dose ([Figure 4](#)). ISL-TP concentrations ( $C_{\text{trough}}$ ) remained above the threshold for 94.4% (34/36) of participants 4 weeks after the first 60 mg dose and for 97.1% (34/35) of participants 4 weeks after the last 60 mg dose, with 1 participant's delayed PK collection time significantly later than 672 hours. ISL-TP

**Table 2. Adverse Event Summary of All Participants as Treated Through the End of the Active Treatment Period<sup>a</sup>**

| Adverse Event                                  | ISL 60 mg<br>(n = 97) | ISL 120 mg<br>(n = 97) | Placebo<br>(n = 48) | Treatment Difference (95% CI) |                       |
|------------------------------------------------|-----------------------|------------------------|---------------------|-------------------------------|-----------------------|
|                                                |                       |                        |                     | ISL 60 mg vs Placebo          | ISL 120 mg vs Placebo |
| Participants with ≥1 AE                        | 58 (59.8)             | 60 (61.9)              | 32 (66.7)           | −6.9 (−22.6 to 10.2)          | −4.8 (−20.5 to 12.1)  |
| Toxicity grade 3–5                             | 3 (3.1)               | 3 (3.1)                | 1 (2.1)             | 0                             | 0                     |
| Serious AEs                                    | 1 (1.0)               | 0                      | 0                   | 1.0 (−6.5 to 5.6)             | 0 (−7.5 to 3.8)       |
| Discontinuation due to AE                      | 1 (1.0)               | 1 (1.0)                | 0                   | 1.0 (−6.5 to 5.6)             | 1.0 (−6.5 to 5.6)     |
| Drug-related <sup>b</sup> AEs                  | 9 (9.3)               | 14 (14.4)              | 12 (25.0)           | −15.7 (−30.5 to −3.3)         | −10.6 (−25.7 to 2.6)  |
| Most common AEs (≥4 participants in any group) |                       |                        |                     |                               |                       |
| Headache                                       | 10 (10.3)             | 9 (9.3)                | 2 (4.2)             | 6.1 (−4.6 to 14.7)            | 5.1 (−5.5 to 13.4)    |
| Nausea                                         | 5 (5.2)               | 7 (7.2)                | 2 (4.2)             | 1.0 (−9.3 to 8.2)             | 3.0 (−7.4 to 10.9)    |
| Diarrhea                                       | 5 (5.2)               | 4 (4.1)                | 4 (8.3)             | −3.2 (−14.9 to 5.0)           | −4.2 (−15.9 to 3.6)   |
| Vomiting                                       | 2 (2.1)               | 4 (4.1)                | 1 (2.1)             | 0 (−9.0 to 5.5)               | 2.0 (−7.1 to 8.5)     |
| Abdominal pain                                 | 3 (3.1)               | 3 (3.1)                | 4 (8.3)             | −5.2 (−16.8 to 2.2)           | −5.2 (−16.8 to 2.2)   |
| Constipation                                   | 4 (4.1)               | 0                      | 2 (4.2)             | 0 (−10.2 to 6.8)              | −4.2 (−14.0 to −0.2)  |
| Upper respiratory tract infection              | 4 (4.1)               | 4 (4.1)                | 3 (6.3)             | −2.1 (−13.1 to 5.2)           | −2.1 (−13.1 to 5.2)   |
| Blood pressure increased                       | 1 (1.0)               | 5 (5.2)                | 0                   | 1.0 (−6.5 to 5.6)             | 5.2 (−2.4 to 11.5)    |
| Proteinuria                                    | 2 (2.1)               | 4 (4.1)                | 1 (2.1)             | 0.0 (−9.0 to 5.5)             | 2.0 (−7.1 to 8.5)     |
| Blood creatine phosphokinase increased         | 1 (1.0)               | 4 (4.1)                | 0                   | 1.0 (−6.5 to 5.6)             | 4.1 (−3.4 to 10.2)    |

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: AEs, adverse events; CI, confidence interval; ISL, islatravir.

<sup>a</sup>The active treatment period was defined as day 1 through 6 weeks (42 days, based on ISL half-life) after the last dose of study intervention (ie, week 26).

<sup>b</sup>Assessed by the investigator to be related to the drug.

**Table 3. Treatment-Related<sup>a</sup> Adverse Events (Incidence ≥2% in Any Treatment Arm) of All Participants as Treated Through Week 24**

| Adverse Event                        | ISL 60 mg<br>(n = 97) | ISL 120 mg<br>(n = 97) | Placebo<br>(n = 48) |
|--------------------------------------|-----------------------|------------------------|---------------------|
| Participants with ≥1 drug-related AE | 9 (9.3)               | 14 (14.4)              | 12 (25.0)           |
| Diarrhea                             | 1 (1.0)               | 2 (2.1)                | 4 (8.3)             |
| Proteinuria                          | 1 (1.0)               | 4 (4.1)                | 1 (2.1)             |
| Abdominal pain                       | 1 (1.0)               | 1 (1.0)                | 3 (6.3)             |
| ALT increased                        | 1 (1.0)               | 0                      | 3 (6.3)             |
| Nausea                               | 0                     | 2 (2.1)                | 2 (4.2)             |
| Headache                             | 2 (2.1)               | 0                      | 1 (2.1)             |
| Pruritus                             | 2 (2.1)               | 0                      | 1 (2.1)             |

Data are presented as No. (%). Every participant was counted a single time for each applicable row and column. A system organ class or specific AE was shown only if its incidence in ≥1 treatment group meets the incidence criterion, after rounding.

Abbreviations: AE, adverse events; ALT, alanine aminotransferase; ISL, islatravir.

<sup>a</sup>Assessed by the investigator to be related to the treatment.

concentrations remained above the threshold for 91.4% (32/35) of participants 4 weeks after the first 120 mg dose, and for all participants 4 weeks after the last 120 mg dose.


## DISCUSSION

After 6 QM oral doses of ISL 60 mg or ISL 120 mg, adults at low risk for acquiring HIV-1 had an AE profile similar to the placebo group. Safety data through the dosing and follow-up periods were similar across groups, with most AEs categorized as mild or moderate and considered unrelated to the study drug. No drug-related serious AEs were reported. Proteinuria was a frequently reported drug-related AE in the ISL 120 mg group (4.1%, all reported from


1 study site), and there was a high incidence of grade 2 treatment-emergent abnormalities in creatinine clearance across participants, with no significant differences between the ISL and placebo groups. Emergent abnormalities in creatinine clearance were transient and resolved. There were no AEs reported relating to weight, body fat distribution, or BMD in ISL 60 mg. Participants in the ISL 120 mg group had small increases (2%–3%) in weight, peripheral fat, and trunk fat at week 24.

Among participants who received ISL, dose-dependent decreases in total lymphocyte counts were observed, which appeared to be partially reversible during the follow-up period, consistent with results from other studies of ISL as treatment showing a recovery toward baseline after drug discontinuation [32]. Total lymphocyte and subset counts beyond week 36 were available only for a subset of participants; data may not represent the entire study population. Consistent with other studies showing lymphocyte decreases with ISL 0.75 mg once daily or ISL 20 mg once weekly as treatment in people with HIV [32, 37], no increase in infection rates was observed in groups treated with ISL compared with placebo during follow-up [38]. The follow-up period was <1 year, however, which may not be sufficient to fully assess the impact on immunocompetence.

This study reports the longest sampling period for oral ISL-TP to date. The terminal elimination  $t_{1/2}$  for oral ISL-TP in PBMCs at 48 weeks after the sixth monthly dose was >470 hours (ie, >2.5 weeks), longer than the 177–209 hours previously reported from studies with shorter PK sampling periods [39, 40]. Effective  $t_{1/2}$  based on accumulation ratio was not determined in this study due to considerable deviations in actual



**Figure 3.** Mean (standard deviation) percentage change from baseline in lymphocyte count over time. Abbreviations: ISL, islatravir; n, number of participants with a test result that met the prespecified criterion.



**Figure 4.** Median (interquartile range) islatravir triphosphate trough concentrations in peripheral blood mononuclear cells at 4 weeks after the first and last dose (A) and at 8, 12, and 16 weeks after the last dose (B). Abbreviations: ISL, islatravir; ISL-TP, islatravir triphosphate; PBMC, peripheral blood mononuclear cell; PK, pharmacokinetics.

PK sample collection, compared with protocol-scheduled timing. These variations resulted from COVID-19–related protocol deviations that permitted flexibility for participants to adjust scheduled study visits. For example, the  $C_{\text{trough}}$  plasma samples for ISL 60 mg were scheduled to be collected 672 hours after the first and last doses; however, the actual collection times ranged from 459 to 2951 hours after the first dose, and from 408 to 1007 hours after the last dose. Such variations also affected other PK parameters, including concentration in a dosing interval,  $C_{\text{max}}$ , and  $\text{AUC}_{0-672}$ . Additionally, alternate clinical laboratory facilities were allowed for sample collection and processing due to logistical implications and shipping restrictions, impacting sample processing.

This placebo-controlled study allowed for a robust, unbiased evaluation of the tolerability and safety profile of ISL monotherapy in a population of adults at low risk of acquiring HIV-1. Except for a dose-dependent decrease in total lymphocyte counts, ISL was well tolerated at 60 mg and 120 mg QM, with a favorable AE profile. A strength of this study is the enrollment of a diverse population reflecting the population that could most benefit from PrEP:  $\geq 80\%$  of the participants were aged  $\leq 45$  years,  $\geq 65\%$  were female, and  $\geq 30\%$  were enrolled in Africa.

Clinical development of oral ISL QM for HIV PrEP has been discontinued due to dose-dependent decreases in total lymphocyte and  $\text{CD4}^+$  T-cell counts seen across the ISL development program [32, 37]. However, ISL continues to be investigated in two 2-drug HIV-1 treatment regimens: an ISL dose of 0.25 mg once daily with doravirine (NCT05631093) and a dose of 2 mg once weekly with lenacapavir (NCT05052996) [38]; the lower dose levels of ISL for treatment have not been associated with decreases in lymphocytes or  $\text{CD4}^+$  T-cell counts. Population pharmacokinetic/pharmacodynamic modeling projects that ISL will achieve efficacious exposures without decreasing lymphocyte and  $\text{CD4}^+$  T-cell counts at these lower dose levels [41, 42].

## CONCLUSIONS

In this randomized, placebo-controlled trial in adults at low risk of acquiring HIV-1, ISL (60 mg and 120 mg) demonstrated tolerability and AE profiles generally comparable to placebo, except for dose-dependent decreases in total lymphocyte counts. Among participants who received ISL, a partial recovery in total lymphocyte counts was observed during the follow-up period in the subset of participants for whom data were available. ISL-TP concentrations for both doses remained above the prespecified PK threshold for prophylaxis of  $0.050 \text{ pmol}/10^6 \text{ PBMCs}$  at the end of the 28-day dosing interval. Although the development of oral ISL QM for HIV-1 PrEP has been terminated due to the concern about lymphocyte toxicity, lower doses of ISL once daily and once weekly continue to be investigated for HIV-1 treatment. The results of this study

highlight the potential of other NRTTIs as long-acting oral PrEP for HIV-1, which could contribute to efforts to end the AIDS epidemic by 2030.

## Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online (<http://jid.oxfordjournals.org/>). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

## Notes

**Acknowledgments.** The authors thank all the individuals who participated in the study. The contributions of the investigators and their staff are also gratefully recognized. Medical writing and/or editorial assistance was provided by Lorna Gcanga, PhD, and Toinette Labuschagné of ApotheCom (Yardley, Pennsylvania, USA). This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA.

**Data availability.** The data sharing policy, including restrictions, of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA, is available at <https://trialtransparency.msclinicaltrials.com/policies-perspectives.aspx>. Requests for access to the clinical study data can be submitted via email to the Data Access mailbox ([dataaccess@msd.com](mailto:dataaccess@msd.com)).

**Financial support.** This work was supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA.

**Potential conflicts of interest.** M. P., R. V., B. H., K. N., B. E., P. W., Y.-P. Z., V. T., P. H., C. M., K. D. K., M. N. R., and R. M. P. are current or former employees of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., and may own stock and/or options in Merck & Co., Inc. S. L. H. has received research grants and consulting fees from Cepheid and MSD, research grants from the National Institutes of Health (NIH), and honoraria from the CROI Foundation board. L.-G. B. has received honoraria from ViiV Healthcare, Gilead Sciences, and MSD. S. A. R. has received clinical research funding from the NIH, Gilead Sciences, and MSD. C. W. H. has received clinical research funding from Gilead Sciences and MSD; grants from the NIH; royalties from Johns Hopkins Technology Ventures; and consulting fees from the Gates Foundation. C. W. H. holds patents related to HIV prevention products licensed by Johns Hopkins to Prionde Biopharma, LLC, which he founded. S. B.-F. has received clinical research funding from the NIH and

MSD. G. N. and Y. C. have received clinical research funding from MSD. A. P. has received consulting fees from MSD, Janssen-Cilag, Astellas Pharma, Pfizer, Novartis, Bayer, BMS, Eisai, Takeda, AstraZeneca, and Merck Serono; has received honoraria from MSD, BMS, Astellas Pharma, Janssen-Oncology, Bayer, Exelixis, Medison, Roche, AstraZeneca, and Merck Serono; and has received support for attending meetings and/or travel from MSD, Pfizer, Astellas Pharma, BMS, and AstraZeneca. All other authors report no potential conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

1. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. **2015**. Available at: <https://www.who.int/publications/i/item/9789241509565>. Accessed 20 September 2024.
2. US Preventive Services Task Force; Barry MJ, Nicholson WK, et al. Preexposure prophylaxis to prevent acquisition of HIV: US Preventive Services Task Force recommendation statement. *JAMA* **2023**; 330:736–45.
3. Joint United Nations Programme on HIV/AIDS. Global AIDS update 2022: in danger. **2022**. Available at: <https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update>. Accessed 20 September 2024.
4. World Health Organization. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. **2024**. Available at: <https://iris.who.int/bitstream/handle/10665/378164/9789240097230-eng.pdf?sequence=1&isAllowed=y>. Accessed 20 September 2024.
5. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. *Lancet* **2020**; 396:239–54.
6. Chou R, Spencer H, Bougatsos C, Blazina I, Ahmed A, Selph S. Preexposure prophylaxis for the prevention of HIV: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* **2023**; 330:746–63.
7. van der Straten A, Montgomery ET, Cheng H, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. *AIDS Behav* **2012**; 16:1775–86.
8. Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-Saharan Africa. *PLoS One* **2016**; 11:e0147743.
9. Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. *N Engl J Med* **2016**; 375:2133–43.
10. Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. *N Engl J Med* **2016**; 375:2121–32.
11. Baeten JM, Palanee-Phillips T, Mgodini NM, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. *Lancet HIV* **2021**; 8:e87–95.
12. Nair G, Celum C, Szyldo D, et al. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. *Lancet HIV* **2023**; 10:e779–89.
13. Population Council. Innovative HIV prevention product for women that promotes choice—dapivirine vaginal ring (DVR)—gains momentum across Africa. **2023**. Available at: <https://popcouncil.org/media/innovative-hiv-prevention-product-for-women-that-promotes-choice-dapivirine-vaginal-ring-dvr-gains-momentum-across-africa/>. Accessed 20 September 2024.
14. Henderson M, Schmidt HA, Chitembo L, et al. The future of pre-exposure prophylaxis (PrEP) for HIV prevention: a global qualitative consultation on provider perspectives on new products and differentiated service delivery. *AIDS Behav* **2023**; 27:3755–66.
15. World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. **2022**. Available at: <https://www.who.int/publications/i/item/9789240054097>. Accessed 20 September 2024.
16. Celum C, Hosek S, Tsholwana M, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. *PLoS Med* **2021**; 18:e1003670.
17. Beesham I, Joseph Davey DL, Beksinska M, Bosman S, Smit J, Mansoor LE. Daily oral pre-exposure prophylaxis (PrEP) continuation among women from Durban, South Africa, who initiated PrEP as standard of care for HIV prevention in a clinical trial. *AIDS Behav* **2022**; 26:2623–31.
18. Mansoor LE, Lewis L, Naicker CL, et al. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa. *J Int AIDS Soc* **2022**; 25:e25957.
19. Cooper SE, Rosenblatt J, Gulick RM. Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries. *Clin Infect Dis* **2022**; 75:S541–8.

20. Liegeon G, Ghosn J. Long-acting injectable cabotegravir for PrEP: a game-changer in HIV prevention? *HIV Med* **2023**; 24:653–63.
21. Koss CA, Gandhi M, Halvas EK, et al. First case of HIV seroconversion with integrase resistance mutations on long-acting cabotegravir for prevention in routine care. *Open Forum Infect Dis* **2024**; 11:ofae468.
22. Matthews RP, Jackson Rudd D, Fillgrove KL, et al. A phase 1 study to evaluate the drug interaction between islatravir (MK-8591) and doravirine in adults without HIV. *Clin Drug Investig* **2021**; 41:629–38.
23. Molina JM, Yazdanpanah Y, Afani Saud A, et al. Brief report: efficacy and safety of oral islatravir once daily in combination with doravirine through 96 weeks for treatment-naïve adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine. *J Acquir Immune Defic Syndr* **2022**; 91:68–72.
24. Schürmann D, Rudd DJ, Zhang S, et al. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naïve adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial. *Lancet HIV* **2020**; 7:e164–72.
25. Matthews RP, Ankrom W, Friedman E, et al. Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV. *Clin Transl Sci* **2021**; 14:1935–44.
26. Matthews RP, Zang X, Barrett SE, et al. A randomized, double-blind, placebo-controlled, phase 1 trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection. *J Acquir Immune Defic Syndr* **2023**; 92:310–6.
27. Markowitz M, Grobler JA. Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. *Curr Opin HIV AIDS* **2020**; 15:27–32.
28. Grobler JA, Fillgrove KL, Hazuda DJ, et al. MK-8591 potency and PK provide high inhibitory quotients at low doses QD and QW [abstract 481]. In: Conference on Retroviruses and Opportunistic Infections, Seattle, WA, **2019**. Available at: <https://user-degqumh.cld.bz/croi2019-abstract-ebook>. Accessed 28 April 2025.
29. Patel M, Zang X, Cao Y, et al. Islatravir PK threshold and dose selection for monthly oral HIV-1 PrEP [abstract 87]. In: Conference on Retroviruses and Opportunistic Infections, Virtual, **2021**. Available at: <https://www.croiconference.org/croi-2021>. Accessed 28 April 2025.
30. Hendrix CW, Hillier SL, Bekker LG, et al. Islatravir distribution in mucosal tissues, PBMC and plasma after monthly oral dosing [abstract 83]. In: Conference on Retroviruses and Opportunistic Infections, Virtual, **2022**. Available at: <https://user-degqumh.cld.bz/CROI-2022-Abstract-eBook>. Accessed 28 April 2025.
31. US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. **2017**. Available at: <https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf>. Accessed 20 September 2024.
32. Squires K, Correll TA, Robertson MN, et al. Effect of islatravir on total lymphocyte and lymphocyte subset counts [abstract 192]. In: Conference on Retroviruses and Opportunistic Infections, Seattle, WA, **2023**. Available at: <https://www.croiconference.org/wp-content/uploads/sites/2/resources/2023/croi2023-abstract-ebookv2.pdf>. Accessed 28 April 2025.
33. Taylor PJ, Tai CH, Franklin ME, Pillans PI. The current role of liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressant and antiretroviral drugs. *Clin Biochem* **2011**; 44:14–20.
34. Sun L, Chavez-Eng C, Fillgrove KL, et al. Toward highly sensitive and reproducible LC-MS/MS analysis of MK-8591 phosphorylated anabolites in human peripheral blood mononuclear cells. *Bioanalysis* **2019**; 11:233–50.
35. Matthews RP, Patel M, Barrett SE, et al. Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial. *Nat Med* **2021**; 27:1712–7.
36. Simiele M, D'Avolio A, Baietto L, et al. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. *Antimicrob Agents Chemother* **2011**; 55:2976–8.
37. Mills AM, Rizzardini G, Ramgopal MN, et al. Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in virologically suppressed adults with HIV-1 on bicitegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. *Lancet HIV* **2024**; 11:e357–68.
38. Squires K, Correll TA, Robertson MN, et al. Incidence of infections across islatravir clinical development programs [abstract EPB204]. In: 12th IAS Conference on HIV Science, Brisbane, Australia, **2023**. Available at: [https://www.iasociety.org/sites/default/files/IAS2023/abstractbook/IAS\\_2023\\_\\_Abstracts.pdf](https://www.iasociety.org/sites/default/files/IAS2023/abstractbook/IAS_2023__Abstracts.pdf). Accessed 28 April 2025.
39. Zang X, Ankrom W, Kraft WK, et al. Intracellular islatravir-triphosphate half-life supports extended dosing intervals. *Antimicrob Agents Chemother* **2024**; 68:e0045824.

40. Matthews RP, Jackson Rudd D, Zhang S, et al. Safety and pharmacokinetics of once-daily multiple-dose administration of islatravir in adults without HIV. *J Acquir Immune Defic Syndr* **2021**; 88:314–21.
41. Vargo R, Robey S, Zang X, et al. Modeling and simulation to optimize islatravir once daily (QD) doses in HIV treatment naive and virologically suppressed populations [abstract O45]. In: *HIV Drug Therapy Glasgow, Glasgow, UK, 2022*. Available at: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.26009>. Accessed 28 April 2025.
42. Vargo R, Robey S, Zang Z, et al. Modeling to optimize islatravir QW dose in HIV virologically suppressed PWH [abstract 497]. In: *Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2023*. Available at: <https://www.croiconference.org/wp-content/uploads/sites/2/resources/2023/croi2023-abstract-ebook-v2.pdf>. Accessed 28 April 2025.